Skip to main content
. 2025 May 30;13(6):1339. doi: 10.3390/biomedicines13061339
ADR adverse drug reaction
ACPA anti-cyclic citrullinated peptide antibody
CDAI clinical disease activity index
cs/b DMARDs synthetic and/or biologic disease-modifying antirheumatic drugs
DAS28 disease activity score
DAS28-CRP disease activity score with C-reactive protein
DAS28-ESR disease activity score with erythrocyte sedimentation rate
DMARD disease-modifying antirheumatic drugs
EGA evaluator global assessment of disease activity
EULAR European Alliance of Associations for Rheumatology
HBV hepatitis B virus
HCV hepatitis C virus
GS gray-scale
JAKi Janus kinases inhibitors
LTB interferon-gamma release assay for latent tuberculosis
MSUS musculoskeletal ultrasonography
MTX methotrexate
NHIF National Health Insurance Fund
NYHA New York Heart Association
OMERACT Outcome Measures in Rheumatology
PD power Doppler
PGA patient global assessment of disease activity
RA rheumatoid arthritis
RCT randomized clinical trials
RF rheumatoid factor
SDAI simplified disease activity index
SH synovial hypertrophy
SJC swollen joint count
TJC tender joint count
TOF tofacitinib
USPD ultrasound power Doppler
UPA upadacitinib
US ultrasound
USGS ultrasound gray-scale